EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy

Zhihui Dong, Zhuoshan Huang, Senlin Li, Ying Wang, Yandan Yao, Xianzhu Yang, Xiaoding Xu

Acta Pharmaceutica Sinica B · 2023-03 · 13 (3) · 955-966

DOI: 10.1016/j.apsb.2022.09.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-03. Verfasst von Zhihui Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Y…. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangdong Science and Technology Department, Guangzhou Municipal Science and Technology Bureau, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibody-based therapy has achieved great success and is now one of the most crucial therapeutic modalities for cancer therapy. The first monoclonal antibody authorized for treating human epidermal growth receptor 2 (HER2)-positive breast cancer is trastuzumab. However, resistance to trastuzumab therapy is frequently encountered and thus significantly restricts the therapeutic outcomes. To address this issue, tumor microenvironment (TME) pH-responsive nanoparticles (NPs) were herein developed for systemic mRNA delivery to reverse the trastuzumab resistance of breast cancer (BCa). This nanoplatform is comprised of a methoxyl-poly (ethylene glycol)-b-poly (lactic-co-glycolic acid) copolymer with a TME pH-liable linker (Meo-PEG-Dlink m -PLGA) and an amphiphilic cationic lipid that can complex PTEN mRNA via electrostatic interaction. When the long-circulating mRNA-loaded NPs build up in the tumor after being delivered intravenously, they could be efficiently internalized by tumor cells due to the TME pH-triggered PEG detachment from the NP surface. With the intracellular mRNA release to up-regulate PTEN expression, the constantly activated PI3K/Akt signaling pathway could be blocked in the trastuzumab-resistant BCa cells, thereby resulting in the reversal of trastuzumab resistance and effectively suppress the development of BCa.

Schlagwörter

Stichwörter der Autor:innen

Cancer therapyMonoclonal antibody therapyNanoparticleTrastuzumab resistancemRNA delivery

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
  • RNA Biomedical Institute, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
  • School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, China.

Förderung

  • Guangdong Science and Technology Department
  • Guangzhou Municipal Science and Technology Bureau
  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2023). Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharmaceutica Sinica B, 13(3), 955-966. https://doi.org/10.1016/j.apsb.2022.09.021

Vancouver

Dong Z, Huang Z, Li S, Wang Y, Yao Y, Yang X, et al. Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharmaceutica Sinica B. 2023;13(3):955-966. doi:10.1016/j.apsb.2022.09.021

BibTeX
@article{Dong2023,
  author = {Dong, Zhihui and Huang, Zhuoshan and Li, Senlin and Wang, Ying and Yao, Yandan and Yang, Xianzhu and Xu, Xiaoding},
  title = {Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {955--966},
  doi = {10.1016/j.apsb.2022.09.021}
}
Kostenlos starten →